SCHEMBL3079162

SCHEMBL3079162

Cc1cccn2ncc(C=O)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHB3 P54753 2/20 0.43
ALDH1A1 P00352 3/20 0.42
TSHR P16473 1/20 0.42
DRD2 P14416 2/20 0.39
DRD4 P21917 2/20 0.39
DRD3 P35462 2/20 0.39
KDM4E B2RXH2 2/20 0.34
MAPT P10636 2/20 0.34
RECQL P46063 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TRIM24 O15164 2/20 0.33
TRIM33 Q9UPN9 2/20 0.33
NPC1 O15118 3/20 0.33
RAB9A P51151 2/20 0.33
ELANE P08246 1/20 0.32
MAPK14 Q16539 1/20 0.31
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
THRB P10828 1/20 0.31
BLM P54132 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29936009 0.86 ALDH1A1 (0.42) EPHB3ALDH1A1TSHRDRD2DRD4
SCHEMBL29935836 0.80 ERN1 (0.44) ALDH1A1TSHRDRD2DRD4DRD3
SCHEMBL24566312 0.79 ERN1 (0.38) EPHB3ALDH1A1DRD2DRD4DRD3
SCHEMBL31439956 0.79 ALDH1A1 (0.38) EPHB3ALDH1A1DRD2DRD4DRD3
SCHEMBL21236685 0.77 EPHB3 (0.46) EPHB3TSHRDRD2DRD4DRD3
SCHEMBL30430886 0.76 EPHB3 (0.39) EPHB3ALDH1A1DRD2DRD4DRD3
SCHEMBL30431275 0.76 DRD2 (0.38) EPHB3DRD2DRD4DRD3
SCHEMBL7519122 0.74 DRD2 (0.36) ALDH1A1TSHRDRD2DRD4DRD3
SCHEMBL3319532 0.73 SMPD3 (0.43) EPHB3ALDH1A1TSHRDRD2DRD4
SCHEMBL21893810 0.73 EPHB3 (0.43) EPHB3ALDH1A1DRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176260-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-04-21 EP claimed
WO-2009008748-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2009-01-15 WO claimed
US-20100226881-A1 PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-09-09 US disclosed
EP-2176260-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-04-21 EP disclosed
WO-2009008748-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100226881-A1 PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY TP53, PNPO, DPYD EPHB3 2757/4885ALDH1A1 588/4885TSHR 1641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.